Comparison of ibritumomab tiuxetan with rituximab, both in combination with BEAM conditioning therapy, in patients with mantle cell lymphoma prior to stem cell transplantation

Trial Profile

Comparison of ibritumomab tiuxetan with rituximab, both in combination with BEAM conditioning therapy, in patients with mantle cell lymphoma prior to stem cell transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top